Kazia Expands Paxalisib Trial Into HR+ Breast Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics has announced plans to expand its ongoing paxalisib clinical trial into hormone...
Kazia Therapeutics
Advertisement
Paxalisib Boosts Anti-Tumor Immunity in Advanced Breast Cancer
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
FDA Grants Priority Review to AstraZeneca’s Baxdrostat NDA for Hard-to-Control Hypertension
Cambridge, UK & Wilmington, Delaware, December 2025 — AstraZeneca has announced that the U.S. Food and Drug Administration has...
Formosa Licenses Ophthalmic Clobetasol Suspension to Rxilient for Asia Commercialization
Taipei, Taiwan, December 2025 — Formosa Pharmaceuticals has announced a licensing agreement with Rxilient Biotech to commercialize clobetasol propionate...
Kazia Therapeutics Secures $50M Private Placement to Strengthen Pipeline Funding
Sydney, Australia, December 3, 2025 — Kazia Therapeutics has announced the pricing of a US $50 million private placement...
Advertisement
